Joelle Hamilton, MD
Medical Oncology · Homewood, ALNPI 1578574851
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $217,797 of the $360,962 with a category attached, or 60.3%. 37 manufacturers reported payments, led by Bayer at 55.1% of the total. Reporting peaked in 2023 at $92,305 and has fallen 80.9% since, to $17,612 in 2025. Among medical oncology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 724 payments — averaging $498.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$199K
- Johnson & Johnson$117K
- Pfizer$25K
- AstraZeneca$5K
- Clovis Oncology, Inc.$4K
- Sanofi$3K
- plus $9K from 31 others
Across 770 payments — averaging $2392.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$873K
- Janssen Research & Development, LLC$509K
- Sumitomo Pharma America, Inc.$234K
- AstraZeneca$224K
- Amgen$2K
What the payments were for
- Consulting fees$98,68127%
- Speaking & faculty fees$217,79760%
- Travel & lodging$31,9249%
- Food & beverage$11,9563%
- Education$6040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 170 | $198,932 |
| Johnson & Johnson | 187 | $116,747 |
| Pfizer | 73 | $24,960 |
| AstraZeneca(2 entities) | 12 | $4,519 |
| Clovis Oncology, Inc. | 3 | $3,700 |
| Sanofi | 17 | $3,035 |
| Ferring Pharmaceuticals Inc. | 1 | $1,824 |
| Janssen Scientific Affairs, LLC | 2 | $1,508 |
| Astellas Pharma US Inc | 55 | $1,236 |
| Merck | 39 | $836 |
| Dendreon Pharmaceuticals LLC | 21 | $640 |
| E.r. Squibb & Sons, L.L.C. | 23 | $353 |
| Eisai Inc. | 22 | $347 |
| Amgen | 9 | $311 |
| Tempus AI, Inc | 10 | $276 |
| Sun Pharmaceutical Industries Inc. | 11 | $261 |
| Novartis | 11 | $215 |
| Progenics Pharmaceuticals, Inc. | 4 | $185 |
| Blue Earth Diagnostics | 6 | $127 |
| Myriad Genetic Laboratories, Inc. | 5 | $112 |
| Exelixis Inc. | 7 | $105 |
| Sumitomo Pharma America, Inc. | 3 | $97 |
| Seagen Inc. | 4 | $96 |
| Gilead | 4 | $89 |
| Telix Pharmaceuticals | 4 | $80 |
| AVEO Pharmaceuticals, Inc. | 4 | $78 |
| AbbVie | 2 | $53 |
| EMD Serono, Inc. | 3 | $47 |
| Myovant Sciences Inc. | 3 | $44 |
| Medtronic | 2 | $34 |
| Mylan Institutional Inc. | 1 | $19 |
| Coherus Oncology, Inc. | 1 | $18 |
| Foundation Medicine, Inc. | 1 | $17 |
| Tolmar, Inc. | 1 | $16 |
| Caris MPI, Inc. | 1 | $16 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $15 |
| Axonics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$360,962 in reported general payments places this provider in the 95th percentile of 30 medical oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 357 | $5,028,122 |
| XtandiEnzalutamide | 338 | $4,439,826 |
| NubeqaDarolutamide | 322 | $4,034,447 |
| OrgovyxRelugolix | 784 | $2,104,924 |
| Abiraterone Acetate | 362 | $480,670 |
| LynparzaOlaparib | 29 | $438,093 |
| AkeegaNiraparib/Abiraterone | 19 | $350,448 |
| TalzennaTalazoparib Tosylate | 17 | $302,026 |
| CabometyxCabozantinib S-Malate | 11 | $257,456 |
| Alendronate Sodium | 273 | $2,490 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 69 | $1,625 |
| Prednisone | 324 | $1,409 |
| Potassium Chloride | 74 | $1,025 |
| Oxycodone Hcl | 41 | $870 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 34 | $860 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada, Akeega | $116,747 | $5,378,570376 claims |
| Astellas Pharma US IncXtandi | $1,236 | $4,439,826338 claims |
| BayerNubeqa | $198,932 | $4,034,447322 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $97 | $2,104,924784 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $1,508 | $480,670362 claims |
| AstraZenecaLynparza | $4,519 | $438,09329 claims |
| PfizerTalzenna | $24,960 | $302,02617 claims |
| Exelixis Inc.Cabometyx | $105 | $257,45611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 30 medical oncology providers in Alabama.
Other medical oncology in Homewood
- Syed Abbas AliJasper$51K
- Pranitha ProdduturvarMobile$33K
- Johnny NacillaCullman$23K
- Michael GarciaJasper$23K
- John WaplesHuntsville$19K
- Susan BostickTuscaloosa$17K
- Brittany CaseDaphne$17K
- Charles LattuadaAnniston$16K
- David HintonTuscaloosa$16K
- James DaughertyFlorence$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.